{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:01:28Z","timestamp":1787032888919,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,20]]},"DOI":"10.7759\/cureus.64988","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T09:43:41Z","timestamp":1721468621000},"source":"Crossref","is-referenced-by-count":2,"title":["Assessment of Vitamin D Status in Primary Hyperparathyroidism Patients: A Retrospective Study"],"prefix":"10.7759","author":[{"given":"Melinda","family":"Kolcsar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya M\u00e1ria","family":"D\u00e9nes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"G\u00e1ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbiomolbio.2006.02.016","article-title":"Vitamin D physiology","volume":"92","author":"Lips P","year":"2006","unstructured":"Lips P. Vitamin D physiology. Prog Biophys Mol Biol. 2006, 92:4-8. 10.1016\/j.pbiomolbio.2006.02.016","journal-title":"Prog Biophys Mol Biol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-016-1169-1","article-title":"Vitamin D and primary hyperparathyroidism: more insights into a complex relationship","volume":"55","author":"Walker MD","year":"2017","unstructured":"Walker MD, Bilezikian JP. Vitamin D and primary hyperparathyroidism: more insights into a complex relationship. Endocrine. 2017, 55:3-5. 10.1007\/s12020-016-1169-1","journal-title":"Endocrine"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4158\/EP.8.4.266","article-title":"Relationship between serum vitamin d status and clinical manifestations of primary hyperparathyroidism","volume":"8","author":"Bandeira F","year":"2002","unstructured":"Bandeira F, Caldas G, Freese E, Griz L, Faria M, Bandeira C. Relationship between serum vitamin d status and clinical manifestations of primary hyperparathyroidism. Endocr Pract. 2002, 8:266-70. 10.4158\/EP.8.4.266","journal-title":"Endocr Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb02043.x","article-title":"Vitamin D status in primary hyperparathyroidism in India","volume":"43","author":"Harinarayan CV","year":"1995","unstructured":"Harinarayan CV, Gupta N, Kochupillai N. Vitamin D status in primary hyperparathyroidism in India. Clin Endocrinol (Oxf). 1995, 43:351-8. 10.1111\/j.1365-2265.1995.tb02043.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12210","article-title":"Vitamin D status in primary hyperparathyroidism: a Southern European perspective","volume":"79","author":"Tassone F","year":"2013","unstructured":"Tassone F, Gianotti L, Baffoni C, et al.. Vitamin D status in primary hyperparathyroidism: a Southern European perspective. Clin Endocrinol (Oxf). 2013, 79:784-90. 10.1111\/cen.12210","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01225","article-title":"Primary hyperparathyroidism","volume":"103","author":"Bilezikian JP","year":"2018","unstructured":"Bilezikian JP. Primary hyperparathyroidism. J Clin Endocrinol Metab. 2018, 103:3993-4004. 10.1210\/jc.2018-01225","journal-title":"J Clin Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-009-0119-x","article-title":"A review of drug-induced hypocalcemia","volume":"27","author":"Liamis G","year":"2009","unstructured":"Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypocalcemia. J Bone Miner Metab. 2009, 27:635-42. 10.1007\/s00774-009-0119-x","journal-title":"J Bone Miner Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/11786388231223604","article-title":"Hypocalcemia in patients with osteoporosis and normal renal function, treated with denosumab, a retrospective analysis","volume":"17","author":"Bitar ZI","year":"2024","unstructured":"Bitar ZI, Hajjiah AM, Maadarani OS, Elzoueiry MM, Gohar MR, Abdelfatah M, Alabdali F. Hypocalcemia in patients with osteoporosis and normal renal function, treated with denosumab, a retrospective analysis. Nutr Metab Insights. 2024, 17:11786388231223604. 10.1177\/11786388231223604","journal-title":"Nutr Metab Insights"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian JP","year":"2022","unstructured":"Bilezikian JP, Khan AA, Silverberg SJ, et al.. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. J Bone Miner Res. 2022, 37:2293-314. 10.1002\/jbmr.4677","journal-title":"J Bone Miner Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick MF","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, et al.. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96:1911-30. 10.1210\/jc.2011-0385","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23043","article-title":"Use of parathyroid function index and Wisconsin index to differentiate primary hyperparathyroidism from secondary hyperparathyroidism: a case-control study","volume":"14","author":"\u00d6zkan MB","year":"2022","unstructured":"\u00d6zkan MB, Turhan VB. Use of parathyroid function index and Wisconsin index to differentiate primary hyperparathyroidism from secondary hyperparathyroidism: a case-control study. Cureus. 2022, 14:e23043. 10.7759\/cureus.23043","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa084","article-title":"Normocalcemic hyperparathyroidism: study of its prevalence and natural history","volume":"105","author":"Schini M","year":"2020","unstructured":"Schini M, Jacques RM, Oakes E, Peel NF, Walsh JS, Eastell R. Normocalcemic hyperparathyroidism: study of its prevalence and natural history. J Clin Endocrinol Metab. 2020, 105:e1171-86. 10.1210\/clinem\/dgaa084","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-27302011000500003","article-title":"Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?","volume":"55","author":"Marques TF","year":"2011","unstructured":"Marques TF, Vasconcelos R, Diniz E, R\u00eago D, Griz L, Bandeira F. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat?. Arq Bras Endocrinol Metabol. 2011, 55:314-7. 10.1590\/s0004-27302011000500003","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone","volume":"88","author":"Maruani G","year":"2003","unstructured":"Maruani G, Hertig A, Paillard M, Houillier P. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab. 2003, 88:4641-8. 10.1210\/jc.2002-021404","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70083-4","article-title":"Subclinical and asymptomatic parathyroid disease: implications of emerging data","volume":"1","author":"Macfarlane DP","year":"2013","unstructured":"Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol. 2013, 1:329-40. 10.1016\/S2213-8587(13)70083-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mporth.2021.07.002","article-title":"Parathyroid hormone and vitamin D: from bench to bedside","volume":"35","author":"Crooks M","year":"2021","unstructured":"Crooks M, Bendall S. Parathyroid hormone and vitamin D: from bench to bedside. Orthop Trauma. 2021, 35:267-73. 10.1016\/j.mporth.2021.07.002","journal-title":"Orthop Trauma"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4158\/EP12371.OR","article-title":"Vitamin D-binding protein levels in female patients with primary hyperparathyroidism","volume":"19","author":"Wang X","year":"2013","unstructured":"Wang X, Shapses SA, Wei S, Sukumar D, Ghosh J. Vitamin D-binding protein levels in female patients with primary hyperparathyroidism. Endocr Pract. 2013, 19:609-13. 10.4158\/EP12371.OR","journal-title":"Endocr Pract"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2010.03.077","article-title":"Vitamin D and primary hyperparathyroidism (PHPT)","volume":"121","author":"Souberbielle JC","year":"2010","unstructured":"Souberbielle JC, Maury E, Friedlander G, Cormier C. Vitamin D and primary hyperparathyroidism (PHPT). J Steroid Biochem Mol Biol. 2010, 121:199-203. 10.1016\/j.jsbmb.2010.03.077","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2008.06.032","article-title":"Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial?","volume":"144","author":"Grubbs EG","year":"2008","unstructured":"Grubbs EG, Rafeeq S, Jimenez C, Feng L, Lee JE, Evans DB, Perrier ND. Preoperative vitamin D replacement therapy in primary hyperparathyroidism: safe and beneficial?. Surgery. 2008, 144:852-8; discussion 858-9. 10.1016\/j.surg.2008.06.032","journal-title":"Surgery"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1177\/0004563214564400","article-title":"Impact of vitamin D replacement in patients with normocalcaemic and hypercalcaemic primary hyperparathyroidism and coexisting vitamin D deficiency","volume":"52","author":"Das G","year":"2015","unstructured":"Das G, Eligar V, Govindan J, Bondugulapati LN, Okosieme O, Davies S. Impact of vitamin D replacement in patients with normocalcaemic and hypercalcaemic primary hyperparathyroidism and coexisting vitamin D deficiency. Ann Clin Biochem. 2015, 52:462-9. 10.1177\/0004563214564400","journal-title":"Ann Clin Biochem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12398","article-title":"Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature","volume":"80","author":"Shah VN","year":"2014","unstructured":"Shah VN, Shah CS, Bhadada SK, Rao DS. Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf). 2014, 80:797-803. 10.1111\/cen.12398","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01473-5","article-title":"Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis","volume":"44","author":"Song A","year":"2021","unstructured":"Song A, Zhao H, Yang Y, Liu S, Nie M, Wang O, Xing X. Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis. J Endocrinol Invest. 2021, 44:1667-77. 10.1007\/s40618-020-01473-5","journal-title":"J Endocrinol Invest"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa174","article-title":"Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism","volume":"105","author":"Palermo A","year":"2020","unstructured":"Palermo A, Naciu AM, Tabacco G, et al.. Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2020, 105:dgaa174. 10.1210\/clinem\/dgaa174","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000502578","article-title":"High rate of occult urolithiasis in normocalcemic primary hyperparathyroidism","volume":"44","author":"Lemos AL","year":"2019","unstructured":"Lemos AL, Andrade SR, Pontes LL, Teixeira PM, Bandeira E, Bandeira LC, Bandeira F. High rate of occult urolithiasis in normocalcemic primary hyperparathyroidism. Kidney Blood Press Res. 2019, 44:1189-95. 10.1159\/000502578","journal-title":"Kidney Blood Press Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4558236","article-title":"Occult renal calcifications in patients with normocalcemic primary hyperparathyroidism and their association with the parathyroid hormone-vitamin D axis","volume":"2022","author":"Victor F","year":"2022","unstructured":"Victor F, Pereira Lemos AL, de Holanda Ribas AM, Bandeira L, Pimentel JH, de Andrade Dam\u00e1zio LO, Bandeira F. Occult renal calcifications in patients with normocalcemic primary hyperparathyroidism and their association with the parathyroid hormone-vitamin D axis. Int J Endocrinol. 2022, 2022:4558236. 10.1155\/2022\/4558236","journal-title":"Int J Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4679","article-title":"Classical and nonclassical manifestations of primary hyperparathyroidism","volume":"37","author":"El-Hajj Fuleihan G","year":"2022","unstructured":"El-Hajj Fuleihan G, Chakhtoura M, Cipriani C, et al.. Classical and nonclassical manifestations of primary hyperparathyroidism. J Bone Miner Res. 2022, 37:2330-50. 10.1002\/jbmr.4679","journal-title":"J Bone Miner Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2017.441","article-title":"The volume of solitary parathyroid adenoma is related to preoperative PTH and 25OH-D3, but not to calcium levels","volume":"13","author":"Gatu A","year":"2017","unstructured":"Gatu A, Velicescu C, Grigorovici A, et al.. The volume of solitary parathyroid adenoma is related to preoperative PTH and 25OH-D3, but not to calcium levels. Acta Endocrinol (Buchar). 2017, 13:441-6. 10.4183\/aeb.2017.441","journal-title":"Acta Endocrinol (Buchar)"},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.4103\/ssj.ssj_79_17","article-title":"Correlations between parathyroid hormone level, adenoma size, and serum calcium level in patients with primary hyperparathyroidism","volume":"6","author":"Al Faifi J","year":"2018","unstructured":"Al Faifi J. Correlations between parathyroid hormone level, adenoma size, and serum calcium level in patients with primary hyperparathyroidism. Saudi Surg J. 2018, 6:122-5.","journal-title":"Saudi Surg J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.11.1848","article-title":"Effect of phosphate on parathyroid hormone secretion in vivo","volume":"14","author":"Estepa JC","year":"1999","unstructured":"Estepa JC, Aguilera-Tejero E, Lopez I, Almaden Y, Rodriguez M, Felsenfeld AJ. Effect of phosphate on parathyroid hormone secretion in vivo. J Bone Miner Res. 1999, 14:1848-54. 10.1359\/jbmr.1999.14.11.1848","journal-title":"J Bone Miner Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2024.101876","article-title":"Vitamin D deficiency or resistance and hypophosphatemia","volume":"38","author":"Sarathi V","year":"2024","unstructured":"Sarathi V, Dhananjaya MS, Karlekar M, Lila AR. Vitamin D deficiency or resistance and hypophosphatemia. Best Pract Res Clin Endocrinol Metab. 2024, 38:101876. 10.1016\/j.beem.2024.101876","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/272562-assessment-of-vitamin-d-status-in-primary-hyperparathyroidism-patients-a-retrospective-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T09:43:45Z","timestamp":1721468625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/272562-assessment-of-vitamin-d-status-in-primary-hyperparathyroidism-patients-a-retrospective-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.64988","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,20]]}}}